Oragenics, Inc.
OGEN
$0.183
$0.0084.57%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -93.55% | -84.48% | -71.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -93.55% | -84.48% | -71.33% |
| Cost of Revenue | -73.44% | 130.20% | 70.07% | 71.35% | 53.79% |
| Gross Profit | 73.37% | -131.69% | -72.52% | -73.85% | -55.45% |
| SG&A Expenses | 18.20% | 41.95% | 40.62% | 36.46% | 21.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.58% | 91.47% | 59.40% | 59.40% | 43.91% |
| Operating Income | 49.49% | -92.16% | -60.86% | -60.91% | -44.96% |
| Income Before Tax | 48.84% | -96.79% | -62.59% | -61.55% | -44.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.84% | -96.79% | -62.59% | -61.55% | -44.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.84% | -96.79% | -62.59% | -61.55% | -44.56% |
| EBIT | 49.49% | -92.16% | -60.86% | -60.91% | -44.96% |
| EBITDA | 49.56% | -92.71% | -61.35% | -61.34% | -45.22% |
| EPS Basic | 78.51% | -36.10% | -18.07% | -27.52% | -21.70% |
| Normalized Basic EPS | 78.51% | -36.09% | -18.06% | -27.51% | -21.60% |
| EPS Diluted | 78.51% | -36.10% | -18.07% | -27.52% | -21.70% |
| Normalized Diluted EPS | 78.51% | -36.09% | -18.06% | -27.51% | -21.60% |
| Average Basic Shares Outstanding | 194.49% | 99.11% | 58.19% | 28.99% | 10.97% |
| Average Diluted Shares Outstanding | 194.49% | 99.11% | 58.19% | 28.99% | 10.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |